Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | FHIT | P49789 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.34 |
| ▸ | CDC7 | O00311 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20489616 | 0.78 | LMNA (0.39) | LMNAADORA3ALDH1A1MAPTHPGD | |
| SCHEMBL20489613 | 0.77 | LMNA (0.46) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL21769050 | 0.72 | LMNA (0.49) | LMNAALDH1A1MAPTHPGDGAA | |
| SCHEMBL11268756 | 0.71 | LMNA (0.70) | LMNAALDH1A1MAPTHPGDCYP1A2 | |
| SCHEMBL20489668 | 0.70 | LMNA (0.47) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL22677871 | 0.69 | LMNA (0.58) | LMNAALDH1A1MAPTHPGDGAA | |
| SCHEMBL2500260 | 0.68 | LMNA (0.45) | LMNAADORA3ALDH1A1MAPTHPGD | |
| SCHEMBL17385268 | 0.67 | LMNA (0.59) | LMNAALDH1A1MAPTHPGDGAA | |
| SCHEMBL20489592 | 0.67 | LMNA (0.46) | LMNAALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL13437895 | 0.66 | LMNA (0.72) | LMNAALDH1A1MAPTHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | LMNA 4276/4885ADORA3 4764/4885ALDH1A1 2879/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | LMNA 4153/4885ADORA3 4805/4885ALDH1A1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.